David A. Morrow

Jan 2, 2024 | jacc.org | David A. Morrow |Eric Velazquez |Akshay S. Desai |Adam D. DeVore

References1. "Angiotensin-neprilysin inhibition versus enalapril in heart failure". N Engl J Med . 2014;371:993-1004. 2. "Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction". N Engl J Med . 2019;381:1609-1620. 3. "Rationale, design and baseline characteristics of the PARAGLIDE-HF trial: sacubitril/valsartan vs valsartan in HFmrEF and HFpEF with a worsening heart failure event". J Card Fail . 2023;29:922-930. 4.

Mar 14, 2023 | medscape.com | David A. Morrow

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log outCancel Abstract and Introduction Abstract Graphical Abstract Diagnostic and prognostic interpretation of serial measurement of high-sensitivity cardiac troponin.